Drugs

Chemotherapy with adjuvant nivolumab versus placebo for GEJ cancer

Photo taken from primewomen.com

Jun 29, 2024, 13:50

Chemotherapy with adjuvant nivolumab versus placebo for GEJ cancer

Syed A. Ahmad, Chief of Surgical Oncology at The University of Cincinnati, made the following post on X:

“Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5)⁦ .”

Additional information.
Source: Syed A. Ahmad/X

cancer chemotherapy gastric cancer gastro-oesophageal junction cancer Hyun Cheol Chung Jen-Shi Chen Jiafu Ji Jong Gwang Kim Keun Won Ryu Li-Tzong Chen Li-Yuan Bai lymph-node dissection Masanori Terashima Min-Hee Ryu Mitsuru Sasako Narikazu Boku nivolumab Norimasa Fukushima OncoDaily Oncology Shinichi Sakuramoto Shunsuke Hagihara Sun Young Rha Syed A. Ahmad Ta-Sen Yeh Tae Yong Kim Takanobu Yamada Takashi Nakada Takeshi Omori The University of Cincinnati Yasunori Nishida Yoon-Koo Kang Yoshinori Hirashima Young Woo Kim

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage